Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines.

Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.

Novartis reports that the Phase III HARBOR study of del-desiran did not meet its primary endpoint in patients with myotonic dystrophy type 1.

Novartis reports that the Phase III Lp(a)HORIZON study of pelacarsen did not meet its primary cardiovascular endpoint in patients with elevated lipoprotein(a) and established cardiovascular disease.

Novartis India is looking at therapy-aligned acquisition opportunities while seeking to deepen its presence in India's Tier 2 and Tier 3 markets.

The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology.

The acquisition adds a novel antibody-drug conjugate payload platform and two preclinical oncology programmes targeting hard-to-treat solid tumours.

The decision makes Itvisma the first and only gene replacement therapy approved in the EU for older children, teenagers and adults living with 5q spinal muscular atrophy. The European Commission has approved Novartis' Itvisma (onasemnogene abeparvovec) for the treatment of older children, teenagers and adults with 5q spinal muscular atrophy (SMA) who have a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. The approval significantly expands access to gene replac